Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

Heart Rhythm

Volumn 5, Issue 3, 2008, Pages 451-459

  Shimano, Masayuki ^a   Tsuji, Yukiomi ^b   Inden, Yasuya ^a   Kitamura, Kazuhisa ^a   Uchikawa, Tomohiro ^a   Harata, Shuji ^a   Nattel, Stanley ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Antiarrhythmic agents; Arrhythmia; Atrium; Heart failure; Remodeling

Indexed keywords

CANDESARTAN; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PIOGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBROSIS; HEART PACING; HEART RATE; HEART VENTRICLE TACHYCARDIA; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FIBROSIS; HEART FAILURE; HYPOGLYCEMIC AGENTS; MALE; RABBITS; TETRAZOLES; THIAZOLIDINEDIONES;

EID: 39649093243     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2007.12.010     Document Type: Article

References (30)

1. Murgatroyd F.D., and Camm A.J. Atrial arrhythmias. Lancet 341 (1993) 1317-1322
2. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100 (1999) 87-95
3. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
4. Nattel S., Shiroshita-Takeshita A., Brundel B.J., et al. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 48 (2005) 9-28
5. Kumagai K., Nakashima H., Urata H., et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 (2003) 2197-2204
6. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
7. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 (2003) 2926-2931
8. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
9. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
10. Ricote M., Li A.C., Willson T.M., et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
11. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
12. Takano H., Nagai T., Asakawa M., et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 87 (2000) 596-602
13. Asakawa M., Takano H., Nagai T., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 (2002) 1240-1246
14. Chen J., and Mehta J.L. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291 (2006) H1738-H1745
15. Chen K., Chen J., Li D., et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 44 (2004) 655-661
16. Shiomi T., Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
17. Iglarz M., Touyz R.M., Viel E.C., et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42 (2003) 737-743
18. Tsuji Y., Zicha S., Qi X.Y., et al. Potassium channel subunit remodeling in rabbits exposed to long-term bradycardia or tachycardia: discrete arrhythmogenic consequences related to differential delayed-rectifier changes. Circulation 113 (2006) 345-355
19. Hanna N., Cardin S., Leung T.K., et al. Differences in atrial vs ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63 (2004) 236-244
20. Lee K.W., Everett T.H., Rahmutula D., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114 (2006) 1703-1712
21. Verheule S., Sato T., Everett T., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94 (2004) 1458-1465
22. Porter K.E., Turner N.A., O'Regan D.J., et al. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64 (2004) 507-515
23. Goette A., Bukowska A., and Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol 7 (2007) 219-224
24. Nattel S., and Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 5 (2006) 1034-1049
25. Shiroshita-Takeshita A., Brundel B.J., Burstein B., et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 74 (2007) 75-84
26. Diep Q.N., El Mabrouk M., Cohn J.S., et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin ii-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105 (2002) 2296-2302
27. Sakai S., Miyauchi T., Irukayama-Tomobe Y., et al. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 103 Suppl 48 (2002) 16S-20S
28. Shibata R., Ouchi N., Ito M., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10 (2004) 1384-1389
29. Tanaka K., Zlochiver S., Vikstrom K.L., et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 101 (2007) 839-847
30. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188